
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is viewed favorably because 3Q26 showed resilient execution, with revenue of $123.8 million, about 9% growth year over year, while adjusted EBITDA of $22.5 million also modestly beat expectations. Its core drivers are strengthening as stent grafts rose 12% and On-X increased 13%, and management tightened FY26 guidance to 8%-10% adjusted constant-currency revenue growth while maintaining roughly $95.5 million of adjusted EBITDA. The outlook is further supported by a meaningful product cycle, with AMDS adoption improving after PMA approval and NEXUS positioned to launch on January 1, 2027, alongside supply investments and expanding international reach.
Bears say
Artivion is exposed to meaningful downside from its heavy reliance on international expansion, since non-North American revenue was 49% of total company revenue in 2024 and is vulnerable to tariffs, corruption exposure, compliance burdens, and reimbursement or legal shifts. Its tissue preservation services are also a critical revenue stream, yet supply can be disrupted by regulatory changes, negative publicity, disease-transmission concerns, or restrictions on tissue distribution, creating structural volatility. On top of that, the company faces substantial quality and regulatory risk, including recalls, EU MDR reclassification, possible FDA reclassification of SGPV to Class III, and EtO-related scrutiny, while the bear case already assumes growth slows to the mid-single digits or lower with disappointing new product launches.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Artivion (AORT) Forecast
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares